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Abstract
Background: Alcoholic hepatitis is characterized by acute, or acute-on-chronic hepatic failure and
associated with a high mortality. Specific therapies should be considered for those at high risk of
mortality. The Mayo End-Stage Liver Disease (MELD) score is a marker of disease severity and
mortality in persons with chronic alcoholic liver disease. Our aims were to assess the utility of the
MELD score as a predictor of short-term mortality in persons with alcoholic hepatitis.
Methods: We assessed the utility of the MELD score and compared it with the Discriminant
Function (DF) as a predictor of mortality in 34 patients hospitalized with alcoholic hepatitis.
Results: The area under the curve of a receiver operating characteristic curve for the MELD score
was 0.82 (confidence intervals 0.65–0.98), and for the DF was 0.86 (confidence intervals 0.70–1.00).
However, the sensitivity and specificity in predicting 30-day mortality for a MELD score of greater
than 11 was 86% and 81%, but for a DF greater than 32 was 86% and 48% respectively. The
presence of ascites and bilirubin greater than 8 mg/dL were also highly predictive of mortality with
a sensitivity of 71% and a specificity of 96%.
Conclusions: Alcoholic hepatitis remains associated with a high mortality in hospitalized patients.
The MELD score performs as well as the DF in predicting mortality at 30 days. A MELD score of
greater than 11, or the presence of both ascites and an elevated bilirubin greater than 8 mg/dL
should prompt consideration of specific therapeutic interventions to reduce mortality.
Background
Alcoholic hepatitis is a manifestation of alcoholic liver in-
jury characterized by necrotizing inflammatory hepatic le-
sions and acute hepatic decompensation. In severe cases,
alcoholic hepatitis is associated with a high mortality [1].
The treatment of alcoholic hepatitis is largely symptomat-
ic, with emphasis on alcohol abstinence and meticulous
attention to nutritional status [2]. Specific therapies such
as corticosteroids and pentoxyfilline need to be consid-
ered as they may reduce mortality in those patients who
are at high risk of dying [3,4]. Thus, the identification of
individuals at high risk of mortality is essential for the
management of persons presenting with alcoholic hepati-
tis.
Persistent alcohol intake may result in collagen deposi-
tion around the central vein with central hyaline sclerosis,
and eventually result in fibrotic lesions. Indeed, alcoholic
Published: 22 January 2002
BMC Gastroenterology 2002, 2:2
Received: 2 December 2001
Accepted: 22 January 2002
This article is available from: http://www.biomedcentral.com/1471-230X/2/2
© 2002 Sheth et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, 
provided this notice is preserved along with the article's original URL.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/2
Page 2 of 5
(page number not for citation purposes)
hepatitis may be superimposed on chronic hepatic insuf-
ficiency or cirrhosis. The Mayo End Stage Liver Disease
(MELD) score is becoming widely used for the prediction
of mortality from end-stage liver disease and is a marker
of disease severity and predictor of mortality in patients
with alcoholic cirrhosis [5]. Furthermore, the individual
components of the MELD score have been described as in-
dividual predictors of mortality from alcoholic hepatitis
in various studies [6–8]. Thus, the MELD score may be
useful as a predictor of mortality in alcoholic hepatitis.
Historically, patients with severe alcoholic hepatitis have
been reported to have a 30-day mortality as high as 50%.
The Discriminant Function (DF) was reported as a predic-
tor of mortality risk based on a retrospective analysis of a
severely ill subgroup of patients performed over 2 decades
ago [3]. A DF score of greater than 32 identified those per-
sons who have a greater than 50% mortality at 1 month,
and who may benefit from corticosteroid therapy [3].
However, the DF requires the use of the prothrombin time
(PT) which has been largely replaced by the International
Normalized Ratio (INR) and is not always reported by
many clinical laboratories.
Our recent clinical experience suggests that the mortality
from alcoholic hepatitis may not be as high as previously
reported. Improvements in critical care management, and
recognition of the importance of nutritional therapy may
account for these observations. However, selection bias
needs to be considered since most reports of predictors of
prognosis in patients with alcoholic hepatitis have been
derived from patients seen at referral centers or enrolled in
clinical trials. Indeed, there is a paucity of information on
community-based survival or prognostic factors for alco-
holic hepatitis. Thus, the aims of our study were (1) to
compare the MELD score with the DF score as a predictor
of short-term mortality in persons with alcoholic hepati-
tis, and (2) to assess prognostic factors for persons with al-
coholic hepatitis seen in contemporary clinical practice.
Methods
Patients and methods
All persons hospitalized at Scott and White Memorial
Hospital between Jan 01, 1997 and Dec 31, 2000 with a
primary admission diagnosis of alcoholic hepatitis (ICD-
9 code of 571.1) were identified using an electronic med-
ical record database. The presence of alcoholic hepatitis
was confirmed on clinical, biochemical and histological
grounds (where available). Demographic, clinical and
laboratory data were obtained retrospectively using the
electronic medical database or by chart review. Survival at
30 and 90 days following the index admission was deter-
mined by chart review or telephone follow-up for all pa-
tients.
Derivation of prognostic scores
The MELD score and modified Maddrey's Discriminant
Function were calculated based on laboratory values ob-
tained within 24 hours of admission. Only those individ-
uals for whom all the required laboratory data were
available within 24 hours of admission were included in
this study. The formula used for the calculations were as
follows: MELD score = 3.8*loge(total bilirubin, mg/dL) +
11.2*loge(INR) + 9.6*loge(creatinine, mg/dL); Upper or
lower limits for the laboratory parameters were not ap-
plied in the derivation of the MELD score in order to ob-
tain a continuous score. Discriminant Function = 4.6*
[patient's PT - control PT] + total bilirubin (mg/dL).
Statistical analysis
The prognostic utility of the MELD score or the DF to pre-
dict mortality at 30 days was assessed by determining the
area under the curve (AUC) of a receiver operating charac-
teristic curve. Analysis of prognostic factors was per-
formed by first identifying the association between
selected demographic, clinical or laboratory variables
with 30-day mortality by univariate analysis using a chi-
squared test. The modeling approach involved first select-
ing the variable with the highest correlation coefficient
with 30-day mortality. Next, the variable with the highest
partial correlation with 30-day mortality was selected,
holding the initial variable constant. This was repeated
until none of the partial correlations were significant.
Figure 1
Receiver Operating Characteristic curves for the utility of
the MELD score for prediction of 30-day mortality in per-
sons hospitalized with alcoholic hepatitis. The area under the
curve (AUC) represents the predictive utility of the MELD
score and is 0.82 (confidence intervals 0.65–0.98).
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Results
Fifty-two persons were identified with an admission diag-
nosis ICD-9 code of 571.1. Eighteen persons did not have
all the necessary laboratory tests within 24 hours of ad-
mission, and were excluded from the analysis. For the 34
patients for whom complete biochemical data were avail-
able, a diagnosis of alcoholic hepatitis was confirmed and
follow-up information obtained by chart review or tele-
phone follow-up. There were 23 men and 11 women with
a mean age of 52 years. Of the 34 patients, 8 persons (6
men and 2 women) had a history of prior admissions for
alcoholic hepatitis and the index admission was felt to
represent an acute exacerbation of chronic alcoholic liver
disease. The remainder had presented with acute alcoholic
hepatitis. One patient had liver biopsy performed which
had revealed histopathological features of steato-hepati-
tis. Three persons had serum antibodies to hepatitis C, but
none had circulating hepatitis B surface antigen. The me-
dian length of hospital stay was 5 days (range 1 to 66
days). The overall 30-day mortality in these patients was
21%, and no additional deaths occurred over the next 60
days. Thus, alcoholic hepatitis remains associated with a
high short-term mortality.
The mean MELD score at admission for survivors at 30-
days was 4.3, while for non-survivors was 18.7. The pre-
dictive utility of the MELD score for prediction of mortal-
ity at 30 days was determined by generating a receiver
operating characteristic curve. The area under the curve
(AUC) for the MELD score was 0.82 (confidence intervals
0.65–0.98) (Fig 1). Using a cut-off of a MELD score of
greater than 11, the sensitivity and specificity of the MELD
score for prediction of 30-day mortality were 86% and
82% respectively.
The DF at admission was also calculated for each person.
The mean DF for survivors was 36.9 and for non-survivors
152.0. However, the AUC for the DF was 0.86 (confidence
intervals 0.70–1.00) (Fig 2). Thus, the performance char-
acteristics of the MELD score is similar to that of the DF.
However, the sensitivity and specificity of a DF>32 were
86% and 48% respectively. Although current practice is to
use a DF cut-off of 32, the specificity of the DF could be
increased to 67% using a cut-off DF score of 42 without al-
tering the sensitivity [9]. Thus, a MELD score of greater
than 11 more accurately identified those persons with al-
coholic hepatitis at high risk of short term mortality. Both
the DF and the MELD score correlated poorly with the
length of hospital stay (correlation coefficient 0.43 and
0.31 respectively).
We next assessed prognostic factors associated with 30-
day mortality amongst our patient population. A variety
of prognostic factors were identified by univariate analysis
(Table 1). A highly significant association was noted for
serum bilirubin, INR, and the presence of ascites or en-
cephalopathy. Of these, an elevated bilirubin greater than
8 mg/dL, and the presence of ascites were highly predic-
tive of mortality. The presence of either bilirubin or ascites
has a sensitivity of 100% and specificity of 56% whereas
the combination of these two factors was highly predictive
of 30-day mortality, with a sensitivity of 71% and a specif-
icity of 96% (Table 2).
Discussion
Both the MELD score and the DF score at admission are
very good predictors of mortality at 30 days. Although a
MELD score of > 11 was more sensitive than a DF of >32,
the differences were small, and unlikely to confer greater
advantage in clinical use. Indeed, the performance charac-
teristics of the two tests based on analysis of their receiver
operating characteristic curves are quite similar. Thus, this
study validates the use of the MELD score as an alternative
to the DF score in predicting short-term mortality in per-
sons with severe alcoholic hepatitis. Because many clinical
laboratories now report the INR, and not the PT control
values, the DF score cannot always be determined. Al-
though the MELD score was not derived from patients
with acute alcoholic hepatitis, it may be useful in selecting
those individuals with alcoholic hepatitis who warrant
specific interventions such as the use of pentoxyfilline or
corticosteroids.
Figure 2
Receiver Operating Characteristic curves for the utility of
the Discriminant Function (DF) for prediction of 30-day mor-
tality in persons hospitalized with alcoholic hepatitis. The
area under the curve (AUC) represents the predictive utility
of the DF score and is 0.86 (confidence intervals 0.70–1.00).
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The serum creatinine level is a component of the MELD
score, but not the DF score. Indeed, the serum creatinine
is highly associated with increased mortality in persons
with end-stage chronic liver disease or cirrhosis. However,
univariate analysis did not identify an association be-
tween an elevated creatinine and short-term mortality in
our patients. Since histopathological confirmation was
not available for all our patients, it was not possible to as-
certain whether the MELD score may be a more useful
prognostic score in those persons with co-existing cirrho-
sis and alcoholic hepatitis.
A barrier to clinical use of the MELD score is the complex-
ity of the formula used to derive the score. Although the
formula can be calculated readily programmed into a
handheld or other computer, many persons will need to
use a calculator to derive the score. Thus, prognostic fac-
tors derived at the bedside and based on simple clinical or
Table 1: Association of Clinical and Laboratory variables with 30-day mortality in patients with alcoholic hepatitis.
Variable Number of patients 30-day mortality, % p Value
Age <46.5 17 6 0.09
>46.5 17 35
Gender Female 11 27 0.66
Male 23 17
Temperature <99.4 27 19 0.61
>99.4 7 29
Abdominal Pain Yes 13 23 1.00
No 21 19
Cirrhosis Yes 19 32 0.1
No 15 7
Encephalopathy Yes 11 45 0.02
No 23 9
Varices Yes 11 27 0.66
No 23 17
Splenomegaly Yes 9 33 0.35
No 25 16
Ascites Yes 17 41 <0.01
No 17 0
Bilirubin (mg/dL) <2 15 7 <0.01
2–5 10 10
5–8 1 0
>8 8 63
Albumin (g/dL) <3 13 38 0.02
3–4 13 0
>4 1 0
Creatinine (mg/dL) <1.5 27 15 0.13
>1.5 7 43
AST/ALT <1.2 3 0 0.12
1.2–1.6 5 0
>1.6 17 27
INR <1.5 20 5 0.01
1.5–2.5 12 42
>1.6 2 50
AST (U/L) <100 9 0 0.15
>100 23 26
ALT (U/L) <100 18 22 1.00
>100 7 14
WBC (×  109/L) <10 24 13 0.07
>10 9 44
Hemoglobin (g/dL) <10 10 20 1.00
>10 23 22
Platelet count (×  109/L) <50 3 33 0.52
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biochemical criteria are likely to be more widely adopted
and used. The presence of ascites, encephalopathy, in-
creased bilirubin, and increased INR were predictive of
30-day mortality in our patients. Indeed, the combination
of a total bilirubin greater than 8 mg/dL and the presence
of ascites was highly predictive of mortality and more spe-
cific than either the MELD or the DF scores.
Conclusions
Alcoholic hepatitis remains associated with a high mortal-
ity in hospitalized patients. The MELD score is an accurate
predictor of short term mortality. A MELD score of greater
than 11 or simple clinical criteria, such as the co-existence
of ascites and a total bilirubin level greater than8 gm/dL
should prompt consideration of specific therapeutic inter-
ventions such as the use of corticosteroids or pentoxyfil-
line to reduce mortality.
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